Prevention Research Branch, Division of HIV/AIDS Prevention, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia.
ORISE Fellow, Oak Ridge Institute for Science and Education, U.S. Department of Energy, Oak Ridge, Tennessee.
AIDS. 2018 Nov 13;32(17):2633-2635. doi: 10.1097/QAD.0000000000001983.
: When combining results from all published surveys, about one in nine global study participants (10.7%) reported ever using preexposure prophylaxis (PrEP) by 2017, a significant increase since US FDA approval in 2012 [odds ratio (OR) = 1.6/year, P < 0.00001]. Moreover, nearly one in six US-based study participants (17.3%) and nearly one in four MSM who met the Centers for Disease Control and Prevention's PrEP indications (24.5%) reported ever using PrEP by 2016. The odds of reporting PrEP use are approximately doubling each year (OR = 1.8/year, P < 0.00001; OR = 2.0/year, P < 0.00001).
在综合所有已发表调查结果后发现，截至 2017 年，约有十分之一的全球研究参与者（10.7%）报告曾使用过暴露前预防（PrEP），自 2012 年美国食品和药物管理局（FDA）批准 PrEP 以来，这一比例显著上升[优势比（OR）=每年 1.6，P<0.00001]。此外，在 2016 年，近六分之一的美国研究参与者（17.3%）和近四分之一符合美国疾病控制与预防中心（CDC）PrEP 适应证的男男性行为者（MSM）（24.5%）报告曾使用过 PrEP。报告 PrEP 使用的几率大约每年翻一番（OR=每年 1.8，P<0.00001；OR=每年 2.0，P<0.00001）。
